Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference77 articles.
1. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity;Ackerman;Nat. Cancer,2021
2. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study;Banerjee;Ann. Oncol.,2018
3. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer;Bardia;J. Clin. Oncol.,2017
4. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer;Bardia;Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.,2021
5. Strategies and challenges for the next generation of antibody-drug conjugates;Beck;Nat. Rev. Drug Disco,2017
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Precision targeting in oncology: The future of conjugated drugs;Biomedicine & Pharmacotherapy;2024-08
2. Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation;Biochemical Pharmacology;2024-08
3. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects;Molecular Pharmaceutics;2024-06-18
4. Will antibody-drug conjugate and immune checkpoint inhibitor-based combination therapy close the gap between benefit and toxicity in the treatment of cancers? A systematic review and meta-analysis;2023-06-28
5. Antibody-drug conjugate monotherapy refines the oncological efficacy as compared to therapy of physicians’ choices in advanced breast cancers: a systematic review and meta-analysis;Translational Breast Cancer Research;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3